

An Exocyclic Methylene Group Acts As a Bioisostere of the 2'-Oxygen Atom in LNA

Punit P. Seth,^{*,†} Charles R. Allerson,[†] Andres Berdeja,[‡] Andrew Siwkowski,[§]
Pradeep S. Pallan,^{||} Hans Gaus,[‡] Thazha P. Prakash,[†] Andrew T. Watt,[§]
Martin Egli,^{||} and Eric E. Swayze[†]

Departments of Medicinal Chemistry, Structural Biology, and Antisense Drug Discovery, Isis Pharmaceuticals, Inc., 1891 Rutherford Road, Carlsbad, California 92008, and Department of Biochemistry, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232

Received July 2, 2010; E-mail: pseth@isisph.com

Abstract: We show for the first time that it is possible to obtain LNA-like (Locked Nucleic Acid **1**) binding affinity and biological activity with carbocyclic LNA (cLNA) analogs by replacing the 2'-oxygen atom in LNA with an exocyclic methylene group. Synthesis of the methylene-cLNA nucleoside was accomplished by an intramolecular cyclization reaction between a radical at the 2'-position and a propynyl group at the C-4' position. Only methylene-cLNA modified oligonucleotides showed similar thermal stability and mismatch discrimination properties for complementary nucleic acids as LNA. In contrast, the close structurally related methyl-cLNA analogs showed diminished hybridization properties. Analysis of crystal structures of cLNA modified self-complementary DNA decamer duplexes revealed that the methylene group participates in a tight interaction with a 2'-deoxyribose residue of the 5'-terminal G of a neighboring duplex, resulting in the formation of a CH...O type hydrogen bond. This indicates that the methylene group retains a negative polarization at the edge of the minor groove in the absence of a hydrophilic 2'-substituent and provides a rationale for the superior thermal stability of this modification. In animal experiments, methylene-cLNA antisense oligonucleotides (ASOs) showed similar *in vivo* activity but reduced toxicity as compared to LNA ASOs. Our work highlights the interchangeable role of oxygen and unsaturated moieties in nucleic acid structure and emphasizes greater use of this bioisostere to improve the properties of nucleic acids for therapeutic and diagnostic applications.

Introduction

Antisense drug discovery technology represents a powerful method to control gene expression in animals and in cell culture.¹ Antisense oligonucleotides (ASOs) bind to their cognate mRNA (mRNA) by Watson–Crick base pairing. Upon binding they can modulate splicing, interfere with translation, or promote degradation of the mRNA by recruitment of RNase H or by degradation via the RISC pathway. Chemical modifications have been used extensively in antisense therapeutics to modulate stability, binding affinity, and pharmacokinetic and toxicological properties of ASOs.² First generation ASOs were fully phosphorothioate (PS) modified DNA oligonucleotides, where one of the oxygen atoms in the backbone phosphodiester linkage is replaced with a sulfur atom.³ The PS linkage protects the ASO against nuclease degradation and promotes binding to plasma proteins thereby permitting distribution to peripheral tissues. However, the PS modification reduces binding affinity

for the target RNA and these ASOs are still subject to nuclease mediated degradation.⁴ Second generation ASOs are chimeric oligonucleotides which have a central gap region of 10 to 16 deoxyribonucleotides flanked on the 3'- and 5'-ends with modified residues such as 2'-O-methoxyethyl nucleotides (MOE). The MOE residues improve affinity for target mRNA and further stabilize the oligonucleotide against exonuclease digestion.^{5,6} Currently there are more than 20 second generation antisense oligonucleotides (ASOs) in various stages of clinical trials for a number of indications including hypercholesterolemia, diabetes, and cancer among others. The most advanced second generation ASO, Mipomersen, an inhibitor of Apolipoprotein B 100 (ApoB 100) biosynthesis,⁷ has shown mean reductions of ~25% in plasma LDL cholesterol in two phase III clinical trials at a dose of 200 mg/week.⁸

In addition to MOE, a number of other 2'-modified ribonucleosides such as 2'-O-methyl and 2'-fluoro have been

[†] Department of Medicinal Chemistry, Isis Pharmaceuticals, Inc.

[‡] Department of Structural Biology, Isis Pharmaceuticals, Inc.

[§] Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc.

^{||} Vanderbilt University.

- (1) Bennett, C. F.; Swayze, E. E. *Annu. Rev. Pharmacol. Toxicol.* **2010**, *50*, 259–93.
- (2) Swayze, E. E.; Bhat, B. In *Antisense Drug Technology: Principles, Strategies, and Applications*, 2nd ed.; Crooke, S. T., Ed.; CRC Press: Boca Raton, FL, 2008; pp 143–182.
- (3) Eckstein, F. *Antisense Nucleic Acid Drug Dev.* **2000**, *10*, 117–21.

(4) Geary, R. S.; Yu, R. Z.; Levin, A. A. *Curr. Opin. Investig. Drugs* **2001**, *2*, 562–73.

(5) Martin, P. *Helv. Chim. Acta* **1995**, *78*, 486–504.

(6) Teplova, M.; Minasov, G.; Tereshko, V.; Inamati, G. B.; Cook, P. D.; Manoharan, M.; Egli, M. *Nat. Struct. Biol.* **1999**, *6*, 535–539.

(7) Crooke, R. M.; Graham, M. J.; Lemonidis, K. M.; Whipple, C. P.; Koo, S.; Perera, R. J. *J. Lipid Res.* **2005**, *46*, 872–84.

(8) Raal, F. J.; Santos, R. D.; Blom, D. J.; Marais, A. D.; Charng, M. J.; Cromwell, W. C.; Lachmann, R. H.; Gaudet, D.; Tan, J. L.; Chasan-Taber, S.; Tribble, D. L.; Flaim, J. D.; Crooke, S. T. *Lancet* **2010**, *375*, 998–1006.

investigated for various antisense applications.⁹ These modifications were found to be tolerated in both the sense and antisense strands of siRNA duplexes¹⁰ and have found applications in improving the therapeutic properties of oligonucleotide aptamers.¹¹ 2'-Fluoro modified ASOs have also found utility as miRNA antagonists where they displayed a remarkable improvement in *in vivo* activity which has been ascribed to altered subcellular pharmacokinetic properties.¹² To further improve the binding affinity of oligonucleotides, Wengel and Imanishi independently introduced 2',4'-methyleneoxy bridged nucleic acids, also commonly known as Locked nucleic acid **1** (LNA).¹³ LNA modified oligonucleotides show unprecedented improvement in the thermal stability of oligonucleotide duplexes.¹⁴ LNA ASOs have also demonstrated promising results for down regulating gene expression,^{15,16} splice modulation,¹⁷ and as micro RNA (miRNA) antagonists¹⁸ in various animal models. However, some LNA ASOs appear to be associated with an increased risk for causing hepatotoxicity.¹⁹

The synthesis of other 2',4'-conformationally restricted nucleoside analogs has been an active area of interest recently given the successful applications of LNA within the antisense paradigm.²⁰ As part of a comprehensive program aimed at understanding the structure–activity relationships (SAR) of ASOs containing LNA and other related conformationally restricted 2',4'-bridged nucleic acids (BNA), we recently reported the synthesis and biological evaluation of 2',4'-constrained Ethyl (cEt) modified nucleic acids **2** (*R*-cEt) and **3** (*S*-cEt).^{21–23} We found that replacing LNA with the cEt modifications resulted in an improvement in the therapeutic profile of “gapmer”²⁴ ASOs targeting *Mus. musculus* phosphatase and tensin homologue (mouse PTEN). We speculated that the improved therapeutic profile of the cEt ASOs was a

result of altered interactions of these ASOs with cellular macromolecules. To investigate if changing the position of the alkyl substituent along the 2',4'-bridging group could provide further improvements in the therapeutic profile, we wished to evaluate substituted carbocyclic LNA (cLNA) analogs **4** (*R*-methyl-cLNA) and **5** (*S*-methyl-cLNA) where the 2'-oxygen atom of LNA was replaced with a substituted carbon atom.

At the time we initiated our synthesis program there were no literature reports describing the synthesis of carbocyclic LNA analogs. We envisaged a strategy where both the *R*- and *S*-methyl-cLNA analogs **4** and **5** as well as other cLNA analogs could be prepared from the methylene-cLNA nucleoside **7** by synthetic manipulation of the exocyclic double bond. For example, the double bond can be hydroborated to provide the hydroxymethyl analog or cleaved oxidatively to provide the keto compound, both of which could serve as intermediates for a myriad of chemical transformations (alkylation, fluorination, reduction, oxidation etc.) to provide other cLNA analogs. Retrosynthetically, methylene-cLNA **7** could be prepared from a suitable nucleoside precursor **8** by means of an intramolecular radical cyclization reaction (Figure 1). This strategy was inspired by previous work by Chattopadhyaya^{25,26} and Matsuda,^{27,28} who independently showed that it was possible to form intramolecular carbon–carbon bonds by generating and trapping a radical at the 2' position of a nucleoside with a suitable acceptor group. We were also motivated to evaluate the antisense properties of the methylene-cLNA **6** itself, as replacing an oxygen atom with a methylene group has been successfully utilized in the antiviral arena (Entecavir)²⁹ and in the search for novel nucleic acid mimics (cyclohexenyl nucleic acids, CeNA).³⁰

While our work was in progress, Chattopadhyaya and co-workers reported the synthesis and biophysical properties of oligonucleotides containing a mixture of *R*- and *S*-methyl-cLNA analogs **4** and **5**.³¹ Since the initial report, Chattopadhyaya has also reported the synthesis and properties of a number of differentially substituted cENA and cLNA analogs (**1a–c**, Figure 2).^{32–34} Recently, Nielsen and co-workers reported the synthesis and biophysical properties of a number of carbocyclic ENA analogs using intramolecular ring closing metathesis and ene-alkyne metathesis reactions (**1d–f**, Figure 2).^{35,36} All the cLNA and cENA analogs reported thus far show moderate to

- (9) Prakash, T. P.; Bhat, B. *Curr. Top. Med. Chem.* **2007**, *7*, 641–649.
 (10) Allerson, C. R.; Sioufi, N.; Jarres, R.; Prakash, T. P.; Naik, N.; Berdeja, A.; Wanders, L.; Griffey, R. H.; Swayze, E. E.; Bhat, B. *J. Med. Chem.* **2005**, *48*, 901–4.
 (11) Ng, E. W.; Shima, D. T.; Calias, P.; Cunningham, E. T., Jr.; Guyer, D. R.; Adamis, A. P. *Nat. Rev. Drug Discovery* **2006**, *5*, 123–32.
 (12) Davis, S.; Propp, S.; Freier, S. M.; Jones, L. E.; Serra, M. J.; Kinberger, G.; Bhat, B.; Swayze, E. E.; Bennett, C. F.; Esau, C. *Nucleic Acids Res.* **2009**, *37*, 70–7.
 (13) Obika, S.; Nanbu, D.; Hari, Y.; Andoh, J.-I.; Morio, K.-I.; Doi, T.; Imanishi, T. *Tetrahedron Lett.* **1998**, *39*, 5401–5404.
 (14) Wengel, J. *Acc. Chem. Res.* **1999**, *32*, 301–310.
 (15) Sapra, P.; Wang, M.; Bandaru, R.; Zhao, H.; Greenberger, L. M.; Horak, I. D. *Nucleosides, Nucleotides Nucleic Acids* **2010**, *29*, 97–112.
 (16) Fluiter, K.; Frieden, M.; Vreijling, J.; Rosenbohm, C.; De Wissel, M. B.; Christensen, S. M.; Koch, T.; Orum, H.; Baas, F. *ChemBioChem* **2005**, *6*, 1104–9.
 (17) Graziewicz, M. A.; Tarrant, T. K.; Buckley, B.; Roberts, J.; Fulton, L.; Hansen, H.; Orum, H.; Kole, R.; Sazani, P. *Mol. Ther.* **2008**, *16*, 1316–22.
 (18) Lanford, R. E.; Hildebrandt-Eriksen, E. S.; Petri, A.; Persson, R.; Lindow, M.; Munk, M. E.; Kauppinen, S.; Orum, H. *Science* **2010**, *327*, 198–201.
 (19) Swayze, E. E.; Siwkowski, A. M.; Wanczewicz, E. V.; Migawa, M. T.; Wyrzykiewicz, T. K.; Hung, G.; Monia, B. P.; Bennett, C. F. *Nucleic Acids Res.* **2007**, *35*, 687–700.
 (20) Zhou, C.; Chattopadhyaya, J. *Curr. Opin. Drug Discovery Dev.* **2009**, *12*, 876–898.
 (21) Swayze, E. E.; Seth, P. P. *PCT Int. Appl.* **2007**, WO 2007/090071.
 (22) Seth, P. P.; Vasquez, G.; Allerson, C. A.; Berdeja, A.; Gaus, H.; Kinberger, G. A.; Prakash, T. P.; Migawa, M. T.; Bhat, B.; Swayze, E. E. *J. Org. Chem.* **2010**, *75*, 1569–81.
 (23) Seth, P. P.; Siwkowski, A.; Allerson, C. R.; Vasquez, G.; Lee, S.; Prakash, T. P.; Wanczewicz, E. V.; Wittchell, D.; Swayze, E. E. *J. Med. Chem.* **2009**, *52*, 10–3.
 (24) Monia, B. P.; Lesnik, E. A.; Gonzalez, C.; Lima, W. F.; McGee, D.; Guinosso, C. J.; Kawasaki, A. M.; Cook, P. D.; Freier, S. M. *J. Biol. Chem.* **1993**, *268*, 14514–22.

- (25) Xi, Z.; Rong, J.; Chattopadhyaya, J. *Tetrahedron* **1994**, *50*, 5255–5272.
 (26) Xi, Z.; Agback, P.; Plavec, J.; Sandström, A.; Chattopadhyaya, J. *Tetrahedron* **1992**, *48*, 349–370.
 (27) Sueda, M.; Shuto, S.; Sugimoto, I.; Ichikawa, S.; Matsuda, A. *J. Org. Chem.* **2000**, *65*, 8988–8996.
 (28) Sueda, M.; Ichikawa, S.; Matsuda, A.; Shuto, S. *J. Org. Chem.* **2003**, *68*, 3465–3475.
 (29) Bisacchi, G. S.; Chao, S. T.; Bachard, C.; Daris, J. P.; Innaimo, S.; Jacobs, G. A.; Kocy, O.; Lapointe, P.; Martel, A.; Merchant, Z.; Slusarchyk, W. A.; Sundeen, J. E.; Young, M. G.; Colonna, R.; Zahler, R. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 127–132.
 (30) Wang, J.; Verbeure, B.; Luyten, I.; Lescrinier, E.; Froeyen, M.; Hendrix, C.; Rosemeyer, H.; Seela, F.; Van Aerschot, A.; Herdewijn, P. *J. Am. Chem. Soc.* **2000**, *122*, 8595–8602.
 (31) Srivastava, P.; Barman, J.; Pathmasiri, W.; Plashkevych, O.; Wenska, M.; Chattopadhyaya, J. *J. Am. Chem. Soc.* **2007**, *129*, 8362–8379.
 (32) Zhou, C.; Plashkevych, O.; Chattopadhyaya, J. *J. Org. Chem.* **2009**, *74*, 3248–3265.
 (33) Zhou, C.; Liu, Y.; Andaloussi, M.; Badgajar, N.; Plashkevych, O.; Chattopadhyaya, J. *J. Org. Chem.* **2009**, *74*, 118–134.
 (34) Xu, J.; Liu, Y.; Dupouy, C.; Chattopadhyaya, J. *J. Org. Chem.* **2009**, *74*, 6534–6554.
 (35) Kumar, S.; Hansen, M. H.; Albæk, N.; Steffansen, S. I.; Petersen, M.; Nielsen, P. *J. Org. Chem.* **2009**, *74*, 6756–6769.
 (36) Albæk, N.; Petersen, M.; Nielsen, P. *J. Org. Chem.* **2006**, *71*, 7731–7740.




Figure 1




Figure 2

significantly reduced binding affinity for complementary RNA relative to LNA that can be partially restored by introducing hydrophilic groups along the 2',4'-bridging substituent. Interestingly, both Chattopadhyaya and Nielsen also showed that cLNA analogs appear to recognize complementary DNA less efficiently relative to RNA. They proposed that replacing the 2'-oxygen atom with carbon reduces the hydration of the duplex in the minor groove which in turn affects recognition of DNA more severely as compared to RNA.^{34,35} Recently, Bramsen and co-workers have reported on the utility of cLNA ASOs for positional modification of sense and antisense strands of siRNA duplexes.^{37,38} In addition, Corey has shown that cLNA ASOs may have utility in selective targeting of mutant

Huntington alleles over wild-type transcripts.^{39,40} However, there are no reports which conclusively explain why cLNA analogs reported thus far show reduced hybridization properties relative to their "oxa" counterparts. Moreover, there are no reports that describe the *in vivo* properties of cLNA modified ASOs. In this manuscript we show for the first time that it is possible to obtain LNA-like binding affinity with cLNA analogs by replacing the 2'-oxygen with an exocyclic methylene group and rationalize the improved thermodynamic properties using crystal structure data. We also report, for the first time, the biological evaluation of cLNA modified ASOs in animal experiments and demonstrate the usefulness of this class of nucleoside modifications for antisense applications.


Results and Discussion

Synthesis of the methylene-cLNA nucleoside commenced from the known 5'-O-TBDPS-3'-O-(2-methylnaphthalene)-allofuranose derivative **9** (Scheme 1).²² Swern oxidation⁴¹ of the primary alcohol followed by a Wittig reaction provided olefin **10** in excellent yield (92%, two steps). Hydroboration of the double bond using 9-BBN/sodium perborate⁴² provided the primary alcohol **11** in good yield (76%). A Swern oxidation of the primary alcohol followed by a Corey–Fuchs⁴³ reaction provided the dibromo olefin **12** (81%, two steps). Attempts to convert **12** directly to the alkyne **15** using *n*BuLi were unsuccessful. Treatment of **12** with *n*BuLi resulted in the formation of a dark green colored solution indicative of single electron transfer into the neighboring naphthylene ring.⁴⁴ To avoid this problem, the naphthyl group (Nap) was deprotected with

- (37) Bramsen, J. B.; Laursen, M. B.; Nielsen, A. F.; Hansen, T. B.; Bus, C.; Langkjaer, N.; Babu, B. R.; Hojland, T.; Abramov, M.; Van Aerschot, A.; Odadzic, D.; Smicius, R.; Haas, J.; Andree, C.; Barman, J.; Wenska, M.; Srivastava, P.; Zhou, C.; Honcharenko, D.; Hess, S.; Muller, E.; Bobkov, G. V.; Mikhailov, S. N.; Fava, E.; Meyer, T. F.; Chattopadhyaya, J.; Zerial, M.; Engels, J. W.; Herdewijn, P.; Wengel, J.; Kjems, J. *Nucleic Acids Res.* **2009**, *37*, 2867–2881.
- (38) Bramsen, J. B.; Pakula, M. M.; Hansen, T. B.; Bus, C.; Langkjaer, N.; Odadzic, D.; Smicius, R.; Wengel, S. L.; Chattopadhyaya, J.; Engels, J. W.; Herdewijn, P.; Wengel, J.; Kjems, J. *Nucleic Acids Res.* **2010**, *38*, 5761–5773.

- (39) Hu, J.; Matsui, M.; Gagnon, K. T.; Schwartz, J. C.; Gabillet, S.; Arar, K.; Wu, J.; Bezprozvanny, I.; Corey, D. R. *Nat. Biotechnol.* **2009**, *27*, 478–84.
- (40) Gagnon, K. T.; Hu, J.; Swayze, E. E.; Bennett, C. F.; Potier, P.; Montallier, C.; Roesch, E.; Lemaitre, M.; Randolph, J.; Deleavy, G.; Damha, M.; Corey, D. CHDI's 5th Annual Huntington's Disease Therapeutics Conference; 2010.
- (41) Mancuso, A. J.; Huang, S.-L.; Swern, D. *J. Org. Chem.* **1978**, *43*, 2480–2482.
- (42) Peng, C. G.; Damha, M. J. *Nucleic Acids Res.* **2005**, *33*, 7019–7028.
- (43) Corey, E. J.; Fuchs, P. L. *Tetrahedron Lett.* **1972**, *13*, 3769–3772.
- (44) Holy, N. L. *Chem. Rev.* **1974**, *74*, 243–277.


Scheme 1



DDQ⁴⁵ to provide **13** (99%), which was further treated with *n*BuLi to provide the alkyne **14** efficiently (97%). Reprotection of the 3'-hydroxyl group as the naphthyl ether provided the desired alkyne **15** (81%). Acetylation of the 1,2-isopropylidene group, followed by synthesis of the nucleoside by means of a Vorbrüggen reaction⁴⁶ with persilylated uracil and deprotection of the 2'-*O*-acetyl group, provided nucleoside **16** in good yield (72%, three steps). The 2'-hydroxyl group in **16** was converted to the thiocarbonate **17** by treatment with tolyl-chlorothionoformate (86%). Treatment of the thiocarbonate **17** with tributyltin hydride and AIBN provided the cyclized nucleoside **18** by means of intramolecular radical cyclization reaction. Interestingly, Chattopadhyaya had previously reported that unsubstituted alkynes do not participate efficiently in intramolecular radical cyclization reactions due to decomposition of the alkyne moiety under the reaction conditions employed (AIBN/*n*Bu₃SnH).²⁵ However, in the case of nucleoside **17**, no further protection of the alkyne was required for efficient cyclization to occur. It is conceivable that, in the case of **17**, the radical cyclization occurs faster than the competing decomposition reactions. The naphthyl protecting group was next cleanly removed using DDQ to provide **19** (62%). Deprotection of the 5'-*O*-TBDPS ether provided nucleoside **20** (69%). Protection of the 5'-hydroxyl group as the 4,4'-dimethoxytrityl (DMTr) ether (96%) followed by a phosphitylation reaction provided the desired amidite **22** in good yield (83%).

The structure of the methylene-cLNA nucleoside was established by NMR spectroscopy. For the 2',4' cyclized nucleoside **18**, the H1', H2', and H3' proton resonances appear as singlets, which is consistent with the furanose ring being locked in the Northern conformation. In addition, the identity of the methylene-cLNA nucleoside was further confirmed by reducing the exocyclic double bond in the 5'-DMTr protected nucleoside **21** using catalytic hydrogenation to provide a separable mixture

Scheme 2



of the known nucleosides **23** and **24** (Scheme 2)(Supporting Information).³¹

Thermal Stability and Mismatch Discrimination Properties of cLNA Analogs. All the modified nucleoside phosphoramidites were incorporated into oligonucleotides using standard phosphoramidite chemistry described previously.²² We first evaluated the cLNA analogs in an oligonucleotide sequence used by Imanishi¹³ to evaluate the hybridization properties of LNA and compared them to *R*-cEt, *S*-cEt, and LNA modified oligonucleotides (Table 1). In this sequence, methylene-cLNA (**A2**, $\Delta T_m + 4.8$ °C/mod. vs RNA, -1.6 °C/mod. vs DNA) showed similar thermal stability versus RNA as LNA (**A7**, $\Delta T_m + 4.5$ °C/mod. vs RNA, $+0.1$ °C/mod. vs DNA), *S*-cEt (**A6**, $\Delta T_m + 4.5$ °C/mod. vs RNA, -0.1 °C/mod. vs DNA), and *R*-cEt (**A5**, $\Delta T_m + 4.7$ °C/mod. vs RNA, -1.1 °C/mod. vs DNA) but reduced stability versus complementary DNA as compared to LNA and *S*-cEt modified oligonucleotides. Chattopadhyaya had previously reported the hybridization properties of a mixture of the *R*-methyl and *S*-methyl thymine nucleobase modified cLNA analogs in a different T_m sequence.³¹ We were able to separate these nucleosides at the 5'-DMTr stage and evaluate the individual isomers in thermal denaturation studies. Evaluation of the *R*-Me-cLNA (**A3**, $\Delta T_m + 2.9$ °C/mod. vs RNA, -3.1 °C/mod. vs DNA) in the Imanishi sequence showed that this isomer did not hybridize complementary RNA or DNA as efficiently as LNA or methylene-cLNA oligonucleotides. The *S*-Me-cLNA (**A4**, $\Delta T_m + 2.0$ °C/mod. vs RNA, -3.9 °C/mod. vs DNA) showed the poorest hybridization properties compared to all the analogs evaluated. In general the cLNA analogs exhibited slightly improved selectivity (as measured by $T_{mRNA} - T_{mDNA}$ /

(45) Xia, J.; Abbas, S. A.; Locke, R. D.; Piskorz, C. F.; Alderfer, J. L.; Matta, K. L. *Tetrahedron Lett.* **2000**, *41*, 169–173.

(46) Vorbrüggen, H.; Bennua, B. *Chem. Ber.* **1981**, *114*, 1279–1286.

Table 1. Thermal Stability Measurements of Methylene-cLNA, *R*-Me-cLNA, *S*-Me-cLNA, *R*-cEt, *S*-cEt, and LNA versus Complementary RNA and DNA in the Imanishi Sequence

Oligomer	Modification	Sequence ^a (5'–3')	T_m^b (°C) vs RNA	ΔT_m (°C)/mod.	T_m (°C) vs DNA	ΔT_m (°C)/mod.	$(T_{m\text{RNA}} - T_{m\text{DNA}})/$ no. mod. (°C)
A1	DNA	d(GCGTTTTTGGCT)	45.6	0	50.9	0	0
A2	Methylene-cLNA	d(GCGTTUTTTGCT)	50.4	+4.8	49.3	−1.6	+1.1
A3	<i>R</i> -Me-cLNA	d(GCGTTUTTTGCT)	48.5	+2.9	47.8	−3.1	+0.7
A4	<i>S</i> -Me-cLNA	d(GCGTTUTTTGCT)	47.6	+2.0	47.0	−3.9	+0.6
A5	<i>R</i> -cEt ^c	d(GCGTTUTTTGCT)	50.3	+4.7	49.8	−1.1	+0.5
A6	<i>S</i> -cEt ^c	d(GCGTTUTTTGCT)	50.1	+4.5	50.8	−0.1	−0.7
A7	LNA ^c	d(GCGTTUTTTGCT)	50.1	+4.5	51.0	+0.1	−0.9

^a Bold letter indicates modified residue. ^b T_m values were measured in 10 mM sodium phosphate buffer (pH 7.2) containing 100 mM NaCl and 0.1 mM EDTA. Sequence of RNA complement: 5'-r(AGCAAAAACGC)-3'. Sequence of DNA complement: 5'-d(AGCAAAAACGC)-3'. ^c Reference 11.

Table 2. Mismatch Discrimination of DNA, Methylene-cLNA, *R*-Me-cLNA, *S*-Me-cLNA, and LNA versus Mismatched RNA Complements

Oligomer	Sequence (5'–3') ^a	$X = A$ (match)	T_m ($\Delta T_m = T_{m(\text{mismatch})} - T_{m(\text{match})}$) (°C) ^b		
			G	C	U
A1 (DNA)	d(GCGTTTTTGGCT)	45.6	41.5 (−4.1)	32.3 (−13.3)	31.8 (−13.8)
A2 (methylene-cLNA)	d(GCGTTUTTTGCT)	50.4	44.6 (−5.8)	34.9 (−15.5)	37.2 (−13.2)
A3 (<i>R</i> -Me-cLNA)	d(GCGTTUTTTGCT)	48.5	42.3 (−6.2)	34.8 (−13.7)	36.3 (−12.2)
A4 (<i>S</i> -Me-cLNA)	d(GCGTTUTTTGCT)	47.6	39.8 (−7.8)	33.4 (−14.2)	35.3 (−12.3)
A8 (LNA) ^c	d(GCGTTUTTTGCT)	50.1	45.0 (−5.1)	35.2 (−14.9)	37.2 (−12.9)

^a Bold letter indicates modified residue. ^b T_m values were measured in 10 mM sodium phosphate buffer (pH 7.2) containing 100 mM NaCl and 0.1 mM EDTA; sequence of RNA complement: 5'-r(AGCAAXAACGC)-3'. ^c Reference 11.

Table 3. Thermal Stability Measurements of Methylene-cLNA, *R*-Me-cLNA, *S*-cEt LNA versus Complementary RNA and DNA in the Herdewijn Sequence

Oligomer	Modification	Sequence (5'–3') ^a	T_m (°C) ^b vs RNA	ΔT_m (°C)/mod.	T_m (°C) vs DNA	ΔT_m (°C)/mod.	$(T_{m\text{RNA}} - T_{m\text{DNA}})/$ no. mod. (°C)
B1	DNA	d(CCAGTGATATGC)	42.6	0	48.7	0	0
B2	Methylene-cLNA	d(CCAGUGAUAUGC)	64.0	+7.1	60.7	+4.0	+1.1
B3	<i>R</i> -Me-cLNA	d(CCAGUGAUAUGC)	58.9	+5.4	54.2	+1.8	+1.6
B4	<i>S</i> -cEt	d(CCAGUGAUAUGC)	61.8	+6.4	59.3	+3.5	+0.8
B5	LNA	d(CCAGUGAUAUGC)	61.0	+6.1	59.4	+3.6	+0.5

^a Bold letter indicates modified residue. ^b T_m values were measured in 10 mM sodium phosphate buffer (pH 7.2) containing 100 mM NaCl and 0.1 mM EDTA. Sequence of RNA complement: 5'-r(GCAUAUCACUGG)-3'. Sequence of DNA complement: 5'-d(GCATACTACTGG)-3'.

number of modifications) for RNA versus DNA as compared to their “oxa” counterparts but the increase was very modest.

We next evaluated the mismatch selectivity of the cLNA analogs versus mismatched RNA complements as reported by Imanishi⁴⁷ and compared them to LNA (Table 2). Methylene-cLNA **A2** and *R*-Me-cLNA **A3** showed comparable (−6 °C) mismatch selectivity while the *S*-Me-cLNA **A4** showed slightly improved (−8 °C) mismatch selectivity for the G–U mismatched pair as compared to LNA (−5 °C). All the cLNA analogs showed excellent selectivity for the C–U (−14 to −16 °C) and the U–U (−12 to −13 °C) mismatched pair which were essentially identical to that observed for LNA.

We also evaluated the hybridization properties of methylene-cLNA and the *R*-Me-cLNA in a different oligonucleotide sequence first described by Herdewijn for the evaluation of HNA and related analogs (Table 3).³⁰ This sequence is a three base

extension of a 9-mer sequence used by Wengel to evaluate the hybridization properties of LNA and allows for three incorporations of U/T monomers at different positions of the oligonucleotide.⁴⁸ In this sequence, the methylene-cLNA (**B2**, ΔT_m +7.1 °C/mod. vs RNA, +4.0 °C/mod. vs DNA) showed excellent hybridization properties which were superior to those of *R*-Me-cLNA (**B3**, ΔT_m +5.4 °C/mod. vs RNA, +1.8 °C/mod. vs DNA) as well as *S*-cEt (**B4**, ΔT_m +6.4 °C/mod. vs RNA, +3.5 °C/mod. vs DNA) and LNA (**B5**, ΔT_m +6.1 °C/mod. vs RNA, +3.6 °C/mod. vs DNA) modified oligonucleotides. As seen with the Imanishi sequence, the methylene-cLNA (+1.1 °C) and *R*-Me-cLNA (+1.6 °C) oligonucleotides showed only slightly improved selectivity for RNA versus DNA as compared to LNA (+0.5 °C) and *S*-cEt (+0.8 °C).

Thus it appears that replacing the 2'-oxygen atom in LNA with an sp³ hybridized carbon atom (analogues **4** and **5**) but not

(47) AbdurRahman, S. M.; Seki, S.; Obika, S.; Yoshikawa, H.; Miyashita, K.; Imanishi, T. *J. Am. Chem. Soc.* **2008**, *130*, 4886–4896.

(48) Koshkin, A. A.; Singh, S. K.; Nielsen, P.; Rajwanshi, V. K.; Kumar, R.; Meldgaard, M.; Olsen, C. E.; Wengel, J. *Tetrahedron* **1998**, *54*, 3607–3630.

Table 4. Selected Crystal and Refinement Data

Oligonucleotide	Vindec	Rmedec	Smedec
Sequence		d(GCGTAU*ACGC)	
Modified nucleotide (U*)	Methylene-cLNA-U E1	<i>R</i> -Me-cLNA-U E2	<i>S</i> -Me-cLNA-U E3
Space group		Orthorhombic $P2_12_12_1$	
Unit cell constants [Å]	$a = 24.42, b = 44.11, c = 45.84$	$a = 26.10, b = 43.49, c = 45.97$	$a = 24.47, b = 44.11, c = 45.95$
$\alpha = \beta = \gamma = 90^\circ$			
Resolution [Å]	1.57	1.59	1.35
Outer shell [Å]	1.63–1.57	1.65–1.59	1.40–1.35
No. of unique reflections	7,592	7,451	11,119
Completeness (outer shell) [%]	99.4 (99.7)	99.7 (97.9)	98.7 (91.7)
R-merge (outer shell) [%]	6.7 (24.8)	5.7 (52.7)	5.9 (43.6)
R-work [%]	16.3	17.2	14.6
R-free [%]	20.8	23.7	18.6
No. of DNA atoms	408	408	408
No. of waters	65	48	78
Rms deviations bonds [Å]	0.022	0.019	0.022
Rms deviations angles [deg]	2.5	2.1	2.4
Avg <i>B</i> -factor, DNA atoms [Å ²]	15.0	22.0	11.9
Avg <i>B</i> -factor, solvent [Å ²]	24.1	32.4	22.2
PDB entry code	3OZ3	3OZ4	3OZ5

an sp^2 hybridized carbon atom (Methylene-cLNA **6**) results in loss of binding affinity for complementary nucleic acids. Moreover, changing the orientation of the methyl group at the sp^3 carbon from the (*R*) (in the minor groove) to the (*S*) (edge of minor groove) configuration appears to diminish the binding affinity for complementary DNA and RNA. Interestingly, Chattopadhyaya recently reported the thermal stability of oligonucleotides containing a cLNA analog where the 2'-oxygen atom is replaced with an unsubstituted methylene group.³⁴ Even in that case, no improvement in binding affinity relative to the mixture of methyl-substituted analogs **4/5** was observed. Consistent with the reports of Nielsen and Chattopadhyaya, we observed an enhancement in recognition of cDNA versus complementary RNA for the cLNA analogs, although the magnitude of stabilization was small and somewhat sequence dependent. Nonetheless, the methylene-cLNA analog **6** represents the first example of a cLNA that shows LNA-like binding affinity without the added need for hydrophilic substituents along the 2'-4'-bridging group to restore duplex hydration.

It is conceivable that the methylene group in **6** does not disrupt the water of hydration around the backbone phosphodiester linkage and in the minor groove and this results in improved binding affinity for complementary nucleic acids relative to analogs **4** and **5** which have a saturated carbon atom at the same position. To test this hypothesis, we examined the crystal structure of methylene-cLNA as well as *R*- and *S*-Me-cLNA modified oligonucleotides incorporated into a self-complementary DNA decamer duplex.⁴⁹

X-ray Crystallographic Studies of DNAs Containing Carbocyclic LNA Analogs. The crystal structures of decamer duplexes with sequence d(GCGTAU*ACGC), whereby U* is methylene-cLNA-U, *R*-Me-cLNA-U, or *S*-Me-cLNA-U were crystallized (Supporting Information) (referred to as Vindec **E1**, Rmedec **E2**, and Smedec **E3**, respectively), and their structures were determined at resolutions of between 1.35 and 1.59 Å (Table 4). The three duplexes adopt an A-form geometry with average values for helical rise and twist of ca. 2.8 Å and 32°, respectively. All of them exhibit a kink of ca. 12° into the major groove that is localized between the T4 and A5 residues (nucleotides of one strand are numbered 1 to 10 and those in the complementary strand are numbered 11 to 20; the modified

cLNA residues are U*6 and U*16). The local compression of that groove goes along with an extended variant of the backbone at residue A5; that is, the α and γ torsion angles are in the *ap* range instead of in the standard *sc*⁻ and *sc*⁺ ranges, respectively. As expected, the conformations of sugars are virtually without exception of the C3'-*endo* type. In particular, the sugars of all six cLNA nucleotides fall into this pucker range.

The overall packing motifs in the three orthorhombic crystal lattices of the Vindec, Rmedec, and Smedec structures are quite similar. Terminal base pairs of duplexes stack against the minor grooves of neighboring DNAs such that each duplex acts as a receptor of two base pairs from nearest neighbors. However, there are subtle differences in the closeness of the interduple contacts that allow insights into the individual electrostatic potentials of cLNA sugars. Thus, in the case of the Vindec duplex, the sugar of residue U*6 engages in a tight interaction with the 2'-deoxyribose moiety of the 5'-terminal G from a neighboring strand (Figure 3A). This leads to formation of a C–H...O-type hydrogen bond between the outer methylene carbon from U*6 and O4' of G1# (# marks a symmetry mate; C...O distance 3.50 Å). By comparison, the packing of duplexes in the Rmedec and Smedec lattices is altered such that the neighboring terminal guanidine does not approach the floor of the minor groove and therefore the *R*- or *S*-methyl substituents of cLNA sugars (Figure 3B and C). These observations provide an indication that the methylene-cLNA moiety retains a negative polarization at the edge of the minor groove in the absence of a hydrophilic 2'-substituent. Conversely, the *R*- and *S*-Me-cLNA sugars in the Rmedec and Smedec structures are poorly hydrated and unable to extend the water structure around the edges of nucleobases toward the phosphate backbone. The interaction between the methylene moiety of U*6 in the Vindec structure is in some ways reminiscent of the environment of the 2'-*O*-allyl substituent in the crystal structure of a decamer duplex of the same sequence containing 2'-*O*-modified uridines at positions 6 and 16.⁵⁰ The outer methylene carbon of the 2'-allyl substituent at U6 displays contacts to four water molecules with distances <3.3 Å. Among these waters, two bridge the outer methylene carbon atoms of the substituents at U6 and U16, whereby the =C(H)₂...O_w distances are 2.88 and 3.28 Å for allyl(U6) and 3.45 and 3.51 Å for allyl(U16). The allyl moieties themselves

(49) Egli, M.; Usman, N.; Rich, A. *Biochemistry* **1993**, *32*, 3221–3237.




Figure 3. Central A5pU*6:A15pU*16 base-pair steps viewed into the minor grooves of the (A) Vindec **E1**, (B) Rmedec **E2**, and (C) Smedec **E3** crystal structures. The strand with residues A5 and U*6 is on the left; carbon, oxygen, nitrogen, and phosphorus atoms are colored in gray, red, blue, and orange, respectively; and carbon atoms of cLNA sugars are highlighted in yellow. Carbon atoms of a 5'-terminal G from a neighboring duplex and an MPD (2-methyl-2,4-pentandiol) molecule in the Vindec crystal are highlighted in green, water molecules are cyan, and hydrogen bonds are thin solid lines.

are spaced at $>5 \text{ \AA}$ across the minor groove and are thus too far apart to allow for effective π - π stacking. Overall, the structural data are in line with the superior RNA affinity of methylene-cLNA modified oligonucleotides and demonstrate that methylene-cLNA analogs offer benefits over other cLNA analogs without the need of introducing hydrophilic chemistry.

Biological Evaluation of Antisense Oligonucleotides Containing Carbocyclic LNA Analogs. Biological evaluation of the methylene-cLNA **6** and the *R*-Me-cLNA **4** modifications was

carried out using two different oligonucleotide sequences (14- and 18-mer) targeting mouse PTEN (Table 5). The 14-mer ASO sequence has a 10-base deoxynucleotide “gap” flanked on the 5' and the 3' end with two modified residues (2–10–2 design) and was described by us previously to characterize the *in vivo* properties of the *R*- and *S*-cEt and LNA “gapmer” ASOs.^{23,51} We first evaluated the ASOs in thermal stability experiments. As seen in the T_m sequences, methylene cLNA ASO **C1** showed similar thermal stability to that of LNA ASO **C3** while the *R*-Me-cLNA ASO **C2** showed lower stability. The slightly improved thermal stability of LNA ASO **C3** could be attributed to the presence of 5-methyl substituents on the pyrimidine nucleobases, which are known to improve the thermal (approximately $+0.5 \text{ }^\circ\text{C}/\text{mod.}$)⁵² and nuclease stability of oligonucleotides.⁵³ The thermal stability observations were essentially recapitulated in the 18-mer sequence where the methylene-cLNA **D1** ASO was similar to LNA ASO **D3** and both were slightly better than *R*-Me-cLNA **D2**. However, the influence of the 5-methyl groups was not as prominent for the 18-mer sequence as compared to the 14-mer sequence. It is conceivable that the 18-mer ASO is capable of forming a more stable duplex (~ 1.7 helical turns) as compared to the 14-mer ASO (~ 1.3 helical turns) and is less influenced by the added stabilization provided by 5-methyl groups on the pyrimidine nucleobases.

The ASOs were next evaluated in cell culture experiments in brain endothelial cells (bEND) using electroporation to assist ASO delivery. For the 14-mer ASOs, the activity in cell culture essentially parallels the T_m data. LNA ASO **C3** ($2.8 \mu\text{M}$) showed the best activity while the cLNA ASOs **C1** ($3.9 \mu\text{M}$) and **C2** ($7.9 \mu\text{M}$) were slightly less potent. For the 18-mer ASOs, the methylene-cLNA ASO **D1** was the most potent ($4.9 \mu\text{M}$) while the *R*-Me-cLNA ASO **D2** ($8.9 \mu\text{M}$) and LNA ASO **D3** ($7.7 \mu\text{M}$) were slightly less active.

ASOs **C1**, **C2**, and **C3** were evaluated in animal experiments using a subchronic dosing schedule. Mice ($n = 4$ per dose group) were injected i.p. with 0.5, 1.5, 5, and 15 mg/kg, twice a week for 3 weeks, of ASOs **C1**, **C2**, and **C3** (Figure 4). PTEN mRNA levels in liver were measured using quantitative RT-PCR 72 h after injection of the last ASO dose and normalized to saline treated animals using protocols described previously.²³ Plasma alanine amino transferase (ALT) levels, a well established marker for liver injury, were measured at sacrifice. The LNA ASO **C3** served as a positive control for the experiment. Dose dependent down regulation of PTEN mRNA in liver tissue was observed for all the ASOs tested. The LNA ASO **C3** was the most potent with an ED_{50} of 3.5 mg/kg. The methylene-cLNA ASO **C1** was slightly less potent ($\text{ED}_{50} = 4.9 \text{ mg/kg}$) while the *R*-Me-cLNA ASO **C2** ($\text{ED}_{50} = 8.7 \text{ mg/kg}$) was the least potent

Table 5. Thermal Stability Measurements and *in Vitro* Activity of Gapmer cLNA ASOs Targeting Mouse PTEN

ASO	Modification	Sequence (5'–3') ^a	T_m^b ($^\circ\text{C}$)	IC_{50}^c (μM)	ED_{50} (mg/kg)
C1	Methylene-cLNA (PS)	CUTAGCACTGGCCU	61.9	3.9	4.9
C2	<i>R</i> -Me-cLNA (PS)	CUTAGCACTGGCCU	57.3	7.9	8.7
C3	LNA ^d (PS)	^m CTTAGCACTGGC ^m CT	65.4	2.8	3.5
D1	Methylene-cLNA (PS)	CUGCTAGCCTCTGGATUU	60.5	4.9	4
D2	<i>R</i> -Me-cLNA (PS)	CUGCTAGCCTCTGGATUU	58.8	8.9	17
D3	LNA (PS)	^m CTGCTAGCCTCTGGATT	61.6	7.7	4

^a Bold letters indicate modified nucleosides in “wings” flanking a central DNA “gap” region; all internucleosidic linkages are phosphorothioate; T = Thymine, U = Uracil, A = Adenine, G = Guanine, C = cytosine, ^mC = 5-methyl cytosine. ^b T_m values were measured in 10 mM sodium phosphate buffer (pH 7.2) containing 100 mM NaCl and 0.1 mM EDTA. Sequence of RNA complement for ASOs **C1**, **C2**, and **C3**: 5'-r(UCAAGGCCAGUGCUAAGAGU)-3'. Sequence for ASOs **D1**, **D2**, and **D3**: 5'-r(UCAAAUCCAGAGGCUAGCAG)-3'. ^c IC_{50} values for ASOs **C1–3** and **D1–3** were determined in mouse bEND cells using electroporation. ^d LNA ASO **C3** with U/C nucleobases in the wings had a T_m of $61.3 \text{ }^\circ\text{C}$.




Figure 4. PTEN mRNA down regulation in liver and plasma ALT levels for mice treated for 3 weeks with methylene-cLNA ASO C1, R-Me-cLNA ASO C2, and LNA ASO C3.




Figure 5. PTEN mRNA down regulation in liver and plasma ALT levels for mice treated with single dose of Methylene-cLNA ASO D1, R-Me-cLNA D2, and LNA ASO D3.

ASO. In this experiment, slight elevations in plasma ALT levels were observed for the LNA ASO C4, while no plasma ALT elevations were observed for ASOs C1 and C2 at the highest dose (15 mg/kg) tested.⁵⁴ For ASOs C1 and C4, maximal knockdown (>90%) of liver PTEN mRNA was observed for mice in the high dose group.

ASOs D1, D2, and D3 were also evaluated in animal experiments. Mice ($n = 4$ per dose group) were injected i.p. with 2, 6, 20, and 60 mg/kg of ASOs D1, D2, and D3, and the plasma ALT levels and PTEN mRNA levels in liver were measured 72 h after the last injection (Figure 5). Dose dependent down regulation of PTEN mRNA in liver was observed for all ASOs tested. The methylene-cLNA ASO D1 and LNA ASO D4 exhibited very similar potencies ($ED_{50} = 4$ mg/kg), while the R-Me LNA ASO was significantly less potent ($ED_{50} = 17$

mg/kg). The big shift in the potency curve for ASO D2 was especially surprising since all these ASOs exhibited very similar IC_{50} values for down regulating PTEN mRNA in cell culture experiments (Table 5). The Methylene-cLNA ASO D1 and the R-Me-cLNA ASO D2 showed modest to no elevations in ALT levels at the highest dose evaluated, while the LNA ASO was toxic at the high dose.

Conclusion

We show for the first time that it is possible to obtain LNA-like binding affinity using cLNA analogs by replacing the 2'-oxygen atom with an exocyclic methylene group. Methylene-cLNA 6 modified ASOs showed improved hybridization for complementary nucleic acids relative to the close structurally related methyl substituted cLNA analogs 4 and 5. We also show that, in the case of cLNA analogs 4 and 5, the relative orientation of the methyl group (inside the minor groove for R-Me-cLNA 4 and at the edge of the minor groove for S-Me-cLNA 5) affects the thermal stability of duplexes containing these modifications. The cLNA modifications appear to improve the recognition of cognate RNA over DNA, but the magnitude of stabilization is small and somewhat sequence dependent. Analysis of crystal structures of the cLNA analogs incorporated into a self-complementary DNA decamer duplex revealed that the methylene group participates in a tight interaction with a 2'-deoxyribose residue of the 5'-terminal G of a neighboring duplex resulting in the formation of a CH...O type hydrogen bond. This interaction shows that the methylene-cLNA retains a negative polarization at the edge of the minor groove in the absence of a hydrophilic 2'-substituent and provides a rationale for the enhanced thermal stability of methylene-cLNA modified oligonucleotides. Conversely, the sugar residues in the R- and S-Me-cLNA analogs are poorly hydrated and unable to extend the water structure around the edges of nucleobases toward the phosphate backbone.

Evaluation of gapmer ASOs in cell culture indicated that the methylene-cLNA ASOs were generally as active as LNA, while the R-Me-cLNA ASOs were slightly less potent. However, it appears that the potency differences are magnified when the ASOs were tested in animal experiments. The *in vivo* data for the 18-mer ASOs D1, D2, and D3 were especially remarkable since all of them showed very similar thermal stability and activity in cell culture but the R-Me-cLNA ASO D2 was 4-fold less active in animals. This suggests that subtle differences in structure between closely related chemically modified ASOs can have a significant impact on their *in vivo* properties. In this regard, our work helps to further understand the intricate nature of structure-activity relationships of chemically modified ASOs and lays the groundwork for identifying optimal designs of cLNA analogs for future *in vivo* applications. Moreover, this work also highlights the interchangeable role of oxygen and unsaturated moieties in nucleic acid structure and emphasizes greater use of this bioisostere to improve the properties of nucleic acids for therapeutic and diagnostic applications.

Acknowledgment. This work was supported in part by NIH Grant R01 GM55237 (to M.E.). We would like to thank Merry Daniel for help with the crystallization experiments and Dr. Karsten Schmidt for HRMS measurements. Vanderbilt University is a member institution of LS-CAT at the Advanced Photon Source (Argonne, IL). Use of the APS was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Science, under Contract No. W-31-109-Eng-38.

(50) Egli, M.; Minasov, G.; Tereshko, V.; Pallan, P. S.; Teplova, M.; Inamati, G. B.; Lesnik, E. A.; Owens, S. R.; Ross, B. S.; Prakash, T. P.; Manoharan, M. *Biochemistry* **2005**, *44*, 9045–57.

(51) Prakash, T. P.; Siwkowski, A.; Allerson, C. R.; Migawa, M. T.; Lee, S.; Gaus, H. J.; Black, C.; Seth, P. P.; Swayze, E. E.; Bhat, B. *J. Med. Chem.* **2010**, *53*, 1636–50.

(52) Freier, S. M.; Altmann, K. H. *Nucleic Acids Res.* **1997**, *25*, 4429–43.

(53) Terrazas, M.; Kool, E. T. *Nucleic Acids Res.* **2009**, *37*, 346–353.

(54) Elevations in ALT levels using LNA ASO C3 have been reproduced in several animal experiments using the described dosing regimen.

Supporting Information Available: General experimental procedures for synthesis of **10–28**; ^1H and ^{13}C NMR spectra and analytical data for all new compounds; ^{31}P NMR spectra for all phosphoramidites; analytical data for oligonucleotides and dose response curves for cell culture experiments are provided. Atomic coordinates and structure factor data for

the three crystal structures have been deposited in the Protein Data Bank (Entry codes 3OZ3, 3OZ4 and 3OZ5). This material is available free of charge via the Internet at <http://pubs.acs.org>.

JA105875E